* Patients showed rise in overall survival and survival
without cancer worsening
* Independent panel recommends patients on placebo shift to
* Medivation shares rises 10 percent before the bell
(Adds details, stock movement)
Oct 22 Medivation Inc and its Japanese
partner Astellas Pharma Inc said their prostate cancer
treatment improved patient survival in a late-stage trial
testing the drug for use in a wider population.
Medivation shares rose 10 percent before the bell after the
companies said the treatment, Xtandi, met both the main goals of
Xtandi is currently approved for treating patients with
advanced prostate cancer who have previously received a
Patients treated with Xtandi in the latest trial showed a
statistically significant increase in their overall survival, as
well as survival without the cancer worsening, compared with
those on placebo.
The late-stage study, named Prevail, tested the drug in more
than 1,700 men with advanced prostate cancer that progressed
despite hormone therapy and who have not yet received
Patients in the study treated with the drug, also known as
enzalutamide, had a median overall survival of 32.4 months,
compared with 30.2 months for those on placebo.
An independent safety committee monitoring the trial
recommended that the study be stopped and all patients be
treated with enzalutamide, the companies said in a joint
"To my knowledge, the benefits in overall survival and
radiographic progression-free survival reported ... are
unprecedented in this patient population," said Tomasz Beer, a
deputy director of Knight Cancer Institute at the Oregon Health
& Science University and an investigator for the study.
Medivation and Astellas will initiate regulatory meetings
beginning in early 2014.
Medivation shares rose 10 percent to $54.97 in premarket
trade. They closed at $49.82 on the Nasdaq on Monday.
(Reporting by Esha Dey in Bangalore; Editing by Sriraj